NORM

Norm Therapeutics is a biotechnology company focused on developing a novel class of tRNA-based therapies to treat genetic diseases caused by nonsense mutations. By leveraging a proprietary platform to design and optimize suppressor tRNAs, the company aims to enable the cellular machinery to read through premature stop codons and restore the production of full-length, functional proteins. This approach has the potential to address a wide range of inherited disorders, including cystic fibrosis and Duchenne muscular dystrophy, where a significant portion of patients carry nonsense mutations. Norm Therapeutics is currently in the pre-clinical stage, advancing its pipeline of RNA-based candidates toward clinical development.